Clinical Trials for Ovarian Cancer

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with recurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancer after prior systemic therapy are randomized to avutometinib (a dual RAF/MEK “clamp”) plus defactinib (FAK/Pyk2 inhibitor) versus investigator’s choice of pegylated liposomal doxorubicin, weekly paclitaxel, letrozole, or anastrozole. Requires measurable disease, ECOG 0–1, and known KRAS status; crossover to the combo is allowed at progression.

ClinicalTrials.gov ID: NCT06072781

A Phase 2 Study of Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Platinum‑resistant high‑grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian‑tube cancer (1–3 prior lines; prior bevacizumab allowed), ECOG 0–1, measurable disease. Single‑arm regimen adds intermittent relacorilant (selective glucocorticoid receptor modulator to overcome taxane resistance) to nab‑paclitaxel and bevacizumab, given on a 28‑day cycle until progression/toxicity.

ClinicalTrials.gov ID: NCT06906341

Safety and Efficacy of Anti-CD47, ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab in Patients with Recurrent Platinum-resistant Ovarian Cancer: Phase II Study

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Enrolling adult women with measurable, recurrent platinum‑resistant epithelial ovarian cancer (ECOG 0–1; 0–3 prior lines in the platinum‑resistant setting; up to 5 prior lines total; BRCA status known/obtainable), excluding prior PD‑1/PD‑L1, CTLA‑4, CD47/SIRPα therapy or primary platinum‑refractory disease. Therapy combines pegylated liposomal doxorubicin and pembrolizumab with evorpacept (ALX148), a high‑affinity SIRPα‑Fc fusion that blocks CD47 to enhance macrophage‑mediated phagocytosis; treatment is every 21 days with possible maintenance pembrolizumab plus ALX148 after complete response.

ClinicalTrials.gov ID: NCT05467670

Combination Targeted and Hormonal treAtMEnt of Low-gradE Serous Ovarian Cancer in the upfroNt Setting

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Upfront therapy for adult women with measurable low-grade serous ovarian or primary peritoneal carcinoma who are not candidates for primary cytoreduction or have residual disease after suboptimal debulking. Patients receive avutometinib (dual RAF/MEK clamp) plus defactinib (FAK inhibitor) on a 3-weeks-on/1-week-off schedule with continuous letrozole (and ovarian suppression if pre/perimenopausal).

ClinicalTrials.gov ID: NCT06394804

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with platinum-resistant high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer (1–3 prior lines; prior bevacizumab and PARP inhibitor as indicated) are randomized to the CDH6-directed antibody-drug conjugate raludotatug deruxtecan (R-DXd; cleavable linker to DXd topoisomerase I payload) given IV q3w versus investigator’s choice of weekly paclitaxel, pegylated liposomal doxorubicin, gemcitabine, or topotecan. Requires measurable disease, ECOG 0–1, available tumor tissue; excludes prior CDH6/DXd ADCs and patients with active ILD/pneumonitis or significant uncontrolled comorbidities.

ClinicalTrials.gov ID: NCT06161025

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with platinum‑resistant high‑grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer after 1–4 prior lines (prior platinum required; prior bevacizumab and PARPi per standards; mirvetuximab where available) are randomized to rinatabart sesutecan, an FRα‑directed antibody‑drug conjugate delivering a topoisomerase I inhibitor, versus single‑agent chemotherapy (paclitaxel, topotecan, PLD, or gemcitabine). Key exclusions include prior topoisomerase I–containing ADCs, primary platinum‑refractory disease, active CNS mets, bowel obstruction, and symptomatic ascites.

ClinicalTrials.gov ID: NCT06619236

An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deficiency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with recurrent high-grade serous/endometrioid ovarian, primary peritoneal, or fallopian tube cancer that is BRCA1/2-mutated and/or HRD-positive, with prior benefit then progression on PARP inhibitor maintenance, are randomized to tuvusertib (ATR inhibitor) combined with either niraparib (PARP inhibitor) or lartesertib (ATM inhibitor), with a later comparison of the selected combination versus tuvusertib alone. Designed to test whether dual DNA damage response blockade improves response in PARPi-experienced, platinum-sensitive disease.

ClinicalTrials.gov ID: NCT06433219

Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Single-arm study for adult women with recurrent ovarian, fallopian tube, or primary peritoneal carcinoma (platinum-sensitive or -resistant) with prior PARP inhibitor exposure, ECOG 0–1, and measurable disease. Patients receive oral ZEN003694 (pan-BET bromodomain inhibitor targeting BRD2/3/4/BRDT to downregulate HR/MYC programs) plus talazoparib (PARP inhibitor) in 28-day cycles; BRCA status known but not restricted.

ClinicalTrials.gov ID: NCT05071937

A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with recurrent or metastatic solid tumors—including endometrial, head and neck, pancreatic, colorectal, hepatocellular, gastric, urothelial, ovarian, cervical, biliary tract, certain subtypes of breast cancer, and cutaneous melanoma—whose disease has progressed after standard therapy and who have measurable, biopsiable disease. All patients receive ifinatamab deruxtecan, an investigational B7-H3-directed antibody-drug conjugate delivering a topoisomerase I inhibitor, administered intravenously every three weeks.

ClinicalTrials.gov ID: NCT06330064

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with measurable, unresectable locally advanced or metastatic solid tumors that have progressed after standard therapies, enrolled in tumor-specific refractory cohorts (e.g., melanoma post–PD-(L)1, SCCHN post platinum/PD-(L)1, HER2-negative gastric/GEJ, HGS ovarian, cervical, endometrial, urothelial, ESCC, pancreatic, mCRPC, nonsquamous NSCLC without drivers, and HR+/HER2– breast cancer after CDK4/6 and chemo). Single-arm therapy is patritumab deruxtecan (HER3-DXd) 5.6 mg/kg IV q3w, an HER3-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor (DXd).

ClinicalTrials.gov ID: NCT06172478